Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The glucosyl-transferase domain (GTD) is the catalytic N-terminal domain of Clostridium difficile toxin B (TcdB). It is responsible for transferring glucose moieties to Rho-family GTPases, leading to their inactivation and disruption of the actin cytoskeleton. This activity is a major virulence factor in Clostridioides difficile infection (CDI), causing intestinal epithelial damage and inflammation.
Bezlotoxumab: Neutralizes toxin function by blocking receptor binding.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Clostridium difficile Toxin B Glucosyl-Transferase Domain (GTD (TcdB)).